EssilorLuxottica : A support level that should be taken advantage of
| Entry price | Target | Stop-loss | Potential |
|---|
|
€174.52 |
€186.56 |
€170 |
+6.9% |
|---|
Pursuant to the correction that has taken place in recent weeks with respect to the shares in EssilorLuxottica, further downside risk now appears limited by close and important technical support levels at 171.9 EUR.
Summary● The company has a good ESG score relative to its sector, according to Refinitiv.
● The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 28.8 times its estimated earnings per share for the ongoing year.
● With an enterprise value anticipated at 3.4 times the sales for the current fiscal year, the company turns out to be overvalued.
● The valuation of the company is particularly high given the cash flows generated by its activity.
● The overall consensus opinion of analysts has deteriorated sharply over the past four months.
● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
ESSILORLUXOTTICA 
